Jessica Schwaber, Scientific Director, Cell & Gene Therapy, Avectas, sat down with me to discuss her company’s unique cell engineering platform, the recent shift in cell & gene therapy commercial needs, current barriers to realizing the full potential of cell & gene therapy, and much more.

Disrupting Cell Engineering with Non-Viral Modalities - YouTube

Jessica Schwaber, Scientific Director, Cell & Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell & gene...

This was a work about the origins of the population of Madagascar where we found a much complexe admixture than Africans and Austronesians. We found that Chinese people have been involve too.

Working on human DNA is one part of the job that needed focus and rigor. Each milliliter of the sample is precious. Want to see more : https://www.linkedin.com/in/rindra-rakotoarivony-b78000103/detail/recent-activity/shares/

Genes therapy or Autologous transplant on a promising results as it took place in many hospitals as a clinical trial in many patients with Sickle cell disease 

The next generation of DNA sequencers has arrived, and with it, a clash of titans: Illumina, Thermo Fisher and Qiagen are all competing for the clinical diagnostics market.

Next-generation sequencing (NGS) companies are redefining DNA sequencing. What began as small-scale PCR and Sanger sequencing efforts have now mushroomed into a $20Bn market with broad medical implications for cancer and chronic disease, including FDA-approved tests for cystic fibrosis and large-scale cancer genome studies that have led to new targeted therapies.

Illumina controls 75% of this market with its sequencing-by-synthesis (SBS) method. Its closest competitor is Thermo Fisher, which rides on ion semiconductor sequencing (Ion Torrent), followed by Pacific Biosciences’ single molecule real-time (SMRT) sequencing. Together, Thermo Fisher and Pacific Life Sciences control the remaining 25% of the market.

Read more: https://labiotech.eu/ngs-dna-sequencing-illumina-qiagen/

Source: IBM Code

Miro Cupak presents this session at Index - San Francisco 2018.
The sensitive nature of genetic data causes a major concern in genetics - a lot of life-saving information, despite having been collected, is inaccessible. Data discovery is believed to be the key to new breakthroughs. In the session, we tell the story of the Beacon Network, the largest search and discovery engine of human genomic data in the world. The system is a result of years of collaboration between developers, researchers and scientists on a global scale, and the flagship project of the Global Alliance for Genomics and Health. We describe the architecture and technologies behind the system with focus on the technical decisions that allowed us to scale and disrupt the perception of genetic data.